Table 5.
Partial Listing of Cytokine Activity Expressed as MFI
| Cytokine | Control Subjects (n = 11) | HSCT without Complications (n = 33) | GVHD (n = 11) | VOD (n = 5) | Respiratory Insufficiency (n = 3) | P |
|---|---|---|---|---|---|---|
| GM-CSF | 216 ± 28 | 121 ± 74 | 216 ± 349 | 69 ± 51 | 129 ± 104 | .07 |
| GRO-α | 77 ± 23 | 97 ± 151 | 199 ± 438 | 118 ± 115 | 154 ± 255 | .32 |
| HGF | 170 ± 63 | 547 ± 512 | 882 ± 725 | 1037 ± 871 | 954 ± 836 | .01 |
| IL-2 | 412 ± 54 | 105 ± 109 | 133 ± 143 | 76 ± 50 | 67 ± 26 | .30 |
| IL-4 | 195 ± 34 | 53 ± 27 | 62 ± 25 | 61 ± 34 | 56 ± 16 | .48 |
| IL-6 | 40 ± 8 | 31 ± 40 | 64 ± 95 | 91 ± 154 | 30 ± 17 | .01 |
| IL-17F | 425 ± 58 | 116 ± 62 | 190 ± 267 | 88 ± 24 | 113 ± 37 | .34 |
| IFN-β | 412 ± 54 | 229 ± 173 | 471 ± 856 | 198 ± 54 | 228 ± 75 | .40 |
| IP-10 | 305 ± 68 | 1197 ± 1670 | 1639 ± 2399 | 1622 ± 2438 | 1600 ± 1434 | .73 |
| MCP-1 | 367 ± 93 | 1297 ± 1652 | 2011 ± 3648 | 2530 ± 3510 | 1457 ± 2137 | .29 |
| PAI | 9055 ± 748 | 8170 ± 1861 | 8350 ± 2147 | 9263 ± 1712 | 7557 ± 2714 | .36 |
| PDGFBB | 1828 ± 820 | 240 ± 356 | 464 ± 947 | 157 ± 107 | 105 ± 80 | .13 |
| TGF-β | 250 ± 35 | 58 ± 43 | 61 ± 37 | 46 ± 17 | 54 ± 26 | .75 |
| TNF-α | 66 ± 18 | 29 ± 17 | 35 ± 24 | 27 ± 9 | 44 ± 58 | .12 |
| VCAM1 | 2958 ± 1161 | 6267 ± 2628 | 6749 ± 3007 | 8067 ± 2990 | 8456 ± 3893 | .25 |
| VEGF | 131 ± 60 | 71 ± 56 | 86 ± 66 | 98 ± 48 | 56 ± 57 | .36 |
All clinical specimens were obtained at 7:00 AM ± 1 hour. Cytokine profiles for transplant recipients differed markedly from control subjects. Analysis by mixed treatment by subjects ANOVA detected differences between transplant groups with and without complications only for GM-CSF, IL-6, and HGF.